Chemical Modulators for Targeting Autism Spectrum Disorders: From Bench to Clinic
Open Access
Abstract
Autism spectrum disorders (ASD) are neurodevelopmental disorders characterized by diverse behavioral symptoms such as repetitive behaviors, social deficits, anxiety, hyperactivity, and irritability. Despite their increasing incidence, the specific pathological mechanisms of ASD are still unknown, and the degree and types of symptoms that vary from patient to patient make it difficult to develop drugs that target the core symptoms of ASD. Although various atypical antipsychotics and antidepressants have been applied to regulate ASD symptoms, these drugs can only alleviate the symptoms and do not target the major causes. Therefore, development of novel drugs targeting factors directly related to the onset of ASD is required. Among the various factors related to the onset of ASD, several chemical modulators to treat ASD, focused on serotonin (5-hydroxytryptamine, 5-HT) and glutamate receptors, microbial metabolites, and inflammatory cytokines, are explored in this study. In particular, we focus on the chemical drugs that have improved various aspects of ASD symptoms in animal models and in clinical trials for various ages of patients with ASD.Keywords
Funding Information
- KIST Institutional Program (2E31512, 2E31524, 2022-279)
- Korea Foundation for Women In Science, Engineering and Technology (WISET) (2E31512, 2E31524, 2022-279)
This publication has 141 references indexed in Scilit:
- Elevated serum levels of interleukin-17A in children with autismJournal of Neuroinflammation, 2012
- De Novo Gene Disruptions in Children on the Autistic SpectrumNeuron, 2012
- Glutamate receptor dysfunction and drug targets across models of autism spectrum disordersPharmacology Biochemistry and Behavior, 2012
- An Open-Label Naturalistic Pilot Study of Acamprosate in Youth with Autistic DisorderJournal of Child and Adolescent Psychopharmacology, 2011
- D-Cycloserine Facilitates Socially Reinforced Learning in an Animal Model Relevant to Autism Spectrum DisordersBiological Psychiatry, 2011
- Principles of early drug discoveryBritish Journal of Pharmacology, 2011
- Elevated plasma cytokines in autism spectrum disorders provide evidence of immune dysfunction and are associated with impaired behavioral outcomeBrain, Behavior, and Immunity, 2011
- Maternal Immune Activation and Autism Spectrum Disorder: Interleukin-6 Signaling as a Key Mechanistic PathwayNeurosignals, 2010
- Repetitive Self-Grooming Behavior in the BTBR Mouse Model of Autism is Blocked by the mGluR5 Antagonist MPEPNeuropsychopharmacology, 2009
- Strong Association of De Novo Copy Number Mutations with AutismScience, 2007